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With the increasing antibacterial resistance in typhoidal Salmonella and the dearth of novel antimicrobials on the horizon, we risk 
losing our primary defense against widespread morbidity and mortality from enteric fever. During 26–28 March 2019, researchers 
from around the world came together in Hanoi, Vietnam, and shared some of their latest findings on antimicrobial resistance. From 
the 258 abstracts presented at the conference, at least 50 discussed phenotypic and genotypic characteristics of antimicrobial resist-
ance in typhoidal Salmonella, covering data of at least 24 different countries, spanning 5 continents. Here, we summarize the key 
findings, focusing on our global journey ahead.
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HUMANS VS TYPHOIDAL SALMONELLA: THE NEVER-
ENDING ARMS RACE
The chronicle of war between the human population and ty-
phoidal Salmonella (Salmonella enterica serovars Typhi [S. 
Typhi] and Paratyphi [S. Paratyphi] A, B, and C) goes back cen-
turies [1–3]. In the 1800s and the early 1900s, with mortality 
rates of about 30%, enteric fever (typhoid and paratyphoid) rav-
aged many parts of the world, including elite neighborhoods in 
cities like New York in North America and Oxford in the United 
Kingdom [3, 4]. The ferocity of this ghastly disease dwindled 
radically with improved water, sanitation, and hygiene (WASH) 
in resource-rich countries and with the advent of antibiotics, 
which decreased mortality to < 1% [3, 5]. Today, the over-
whelming burden of enteric fever rests disproportionately on 
low- and middle-income countries (LMICs), specifically in 
South Asia and sub-Saharan Africa [6]. The WASH improve-
ments seen in the developed countries have not been effectively 
implemented in LMICs; hence, the primary weapon to fight the 
disease is antibiotics. However, with increasing use of antibiotics 
in these countries, antimicrobial resistance (AMR) is steadily 
rising, and individual resistance to every widely used antibiotic 
to treat enteric fever has been reported. With increasing AMR 
and the slow pace of WASH improvements in LMICs, there is 
rising fear of untreatable infections and returning to the high 
mortality rates experienced in the preantibiotic era.
The first antibiotic to treat typhoid, chloramphenicol, was 
introduced in 1948 [7]. As resistance to chloramphenicol 
started emerging, ampicillin and co-trimoxazole were intro-
duced in the treatment protocol in the 1970s [8]. However, by 
the 1980s, reports of S. Typhi resistant to all 3 drugs—ampi-
cillin, chloramphenicol, and co-trimoxazole (also known as the 
first line of antibiotics)—started emerging. The simultaneous 
resistance to these 3 drugs is defined as multidrug resistance 
(MDR), and this was linked to the emergence of the H58 haplo-
type (or genotype 4.3.1) that carried an IncHI1 plasmid with 
multiple antibiotic resistance genes [9–11]. As a result, the pri-
mary treatment for enteric fever shifted to fluoroquinolones, 
but not surprisingly, with widespread use, soon there were re-
ports of decreasing fluoroquinolone susceptibility due to rise of 
point mutations in the gyrase and topoisomerase genes [12, 13]. 
This left third-generation cephalosporins and azithromycin as 2 
of the very few reliable options to treat enteric fever.
The first cephalosporin-resistant cases were reported from 
Bangladesh in 1998 and 2001, but they appeared to be isolated 
events [14, 15]. In 2016, Pakistan was hit by a typhoid outbreak 
caused by an extensively drug-resistant (XDR) strain of S. Typhi 
that was resistant to chloramphenicol, ampicillin, co-trimoxa-
zole, streptomycin, fluoroquinolones, and third-generation 
cephalosporins [16]. This XDR strain encodes a chromosomally 
located resistance region and carries a plasmid encoding addi-
tional resistance elements, including the blaCTX-M-15 extended-
spectrum β-lactamase, and the qnrS fluoroquinolone resistance 
gene. The primary oral drug available to treat XDR S. Typhi in 
the outpatient department, where the majority of the patients 
are treated, is azithromycin [17]. Meropenem, an injectable an-
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In January 2018, the World Health Organization adopted a 
recommendation for use of typhoid conjugate vaccines (TCVs) 
in settings with high burden of typhoid and has prequalified the 
first TCV [18, 19]. A  recent phase 3 trial in Nepal illustrated 
that a single dose of TCV was immunogenic and effective in re-
ducing bacteremia by S. Typhi in children 9 months to 16 years 
of age [20]. Countries are now facing important decisions about 
whether to provide TCVs and at what geographic scale, and in 
the light of the recent outbreak in Pakistan, these decisions are 
of great consequence for fighting the further rise and spread 
of AMR.
The 11th International Conference on Typhoid and Other 
Invasive Salmonelloses, held in Hanoi, Vietnam, from 26 to 
28 March 2019, brought together researchers from around the 
world to present their most recent findings, take part in discus-
sions, and speculate on the way forward as a global community. 
On the backdrop of the ongoing XDR outbreak in Pakistan, not 
surprisingly, a large proportion of the presented work was ded-
icated to the growing crisis of AMR in typhoidal Salmonella. 
From 258 abstracts, at least 50 abstracts pertained to genomic 
and phenotypic characteristics of AMR. These 50 abstracts cov-
ered data from at least 24 different countries, spanning 5 con-
tinents. The data presented in this conference are some of the 
most globally represented and up-to-date.
SALMONELLA ENTERICA SEROVAR TYPHI: THE 
PROTAGONIST
At least 25 presentations focused on different aspects of AMR 
pertaining to S. Typhi, with 6 presentations dedicated to the on-
going XDR typhoid outbreak in Pakistan. The outbreak, detected 
in 2016, has affected > 10 000 people in Pakistan [21–23]. Farah 
Qamar and her team recently published that risk factors for ac-
quiring XDR S.  Typhi include being male, eating outside the 
home, exposure to a patient with S. Typhi infection, and a his-
tory of antimicrobial use [24]. The XDR cases clustered around 
sewage lines, and S. Typhi DNA was detected in about a fourth of 
community water sources, reasserting the importance of access 
to clean water for decreasing the burden of enteric fever.
Researchers, clinicians, and public health officials in Pakistan 
have come a long way since the group last met 2 years ago in 
Kampala, during the 10th conference in 2017. The recently 
approved TCV has already been introduced in the affected re-
gions, where thousands of children are currently being vaccin-
ated. Following the conference, on 15 November 2019, Pakistan 
became the first country to introduce TCV in its national im-
munization program to control the outbreak and further spread 
of AMR [25]. Mudasser Hussain’s team from Pakistan drew at-
tention to the importance of decreasing injudicious use of anti-
biotics to prevent future outbreaks of this severity and scale.
Since the report of the XDR typhoid outbreak, there have 
been warranted fears of global spread of the XDR strain. At the 
conference, Grace Appiah of the United States (US) Centers for 
Disease Control and Prevention presented 5 travel-related XDR 
cases in the US. As the outbreak continues in Pakistan, addi-
tional cases of XDR S. Typhi have also been reported from the 
United Kingdom, the US, Australia, Denmark, Canada, Spain, 
Taiwan, and Italy [16, 26–31] (Figure 1).
Apart from Pakistan, AMR profiles of S. Typhi were pre-
sented from at least 23 countries. Of specific importance are the 
multicountry Typhoid Fever Surveillance in Africa Program 
Figure 1. Global spread of extensively drug-resistant (XDR) Salmonella Typhi strains that originated in Pakistan. In red is Pakistan, and in gray are countries where travel-
related XDR typhoid cases have been identified up to 20 March 2020. We conducted a PubMed search using the terms “Salmonella Typhi”; “XDR”; “typhoid”; “outbreak”; 
and “travel” in different combinations. We also used the Google search engine to find additional literature or other reliable sources that contained reports on extensively 
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(TSAP) and the Surveillance of Enteric Fever in Asia Project 
(SEAP) studies [32, 33]. TSAP is conducted in 10 different 
countries (Burkina Faso, Ghana, Ethiopia, Kenya, Guinea-
Bissau, Madagascar, Senegal, South Africa, Tanzania, and 
Sudan), and Se Eun Park of the International Vaccine Institute 
presented that 52% of typhoidal Salmonella strains circulating 
in the region are MDR. Similarly, Susan Kavai of the Kenya 
Medical Research Institute presented that 56% of the Typhi 
strains isolated in Kenya are MDR and 18% are fluoroquinolone 
resistant. However, these rates appear to vary between countries 
in Africa. Peter Adikwu’s team in Nigeria detected 27% MDR 
and 56% fluoroquinolone-nonsusceptible S. Typhi strains. 
Tapfumanei Mashe from the Ministry of Health and Child Care 
Zimbabwe described a gradual increase in fluoroquinolone re-
sistance (from 0% in 2012 to 22% in 2017), and pointed toward 
a potential outbreak where all the strains were fluoroquinolone 
resistant.
SEAP is conducted in 3 countries in South Asia (Bangladesh, 
Pakistan, and Nepal). Preliminary AMR data presented by 
Muhammad Tahir Yousafzai of this multicountry study de-
picted low rates of MDR (18% in S. Typhi and 1% S. Paratyphi 
A) but high rates of fluoroquinolone nonsusceptibility in both 
Bangladesh and Nepal (> 90%). In Pakistan, on the other 
hand, 85% of the circulating S. Typhi strains were found to 
be XDR. Interestingly, several independent studies from India 
and Myanmar (Sriparna Samajpati et al, Bhaskar Shenoy et al, 
and Tin Ohn Myat et al) noted a reduction of MDR and high 
prevalence of fluroquinolone nonsusceptibility among S. Typhi 
strains in these countries.
With the rise in fluroquinolone resistance and increasing 
cases of XDR S. Typhi, azithromycin is the only reliable 
oral drug available against typhoid. Historical reports of 
azithromycin resistance are rare. However, its increasing use 
places selective pressure for the emergence and spread of 
azithromycin-resistant isolates. Researchers of the Strategic 
Typhoid Alliance Across Africa and Asia (STRATAA) study 
reported azithromycin resistance of 21% in Bangladesh and 
2.8% in Nepal, but nonexistent in Malawi. Senjuti Saha’s team 
from the Child Health Research Foundation of Bangladesh 
dedicated a talk to azithromycin resistance and described 12 
cases of azithromycin-resistant S. Typhi strains and the mo-
lecular mechanism conferring such resistance [34]. Her team 
showed that azithromycin resistance is gradually increasing in 
Bangladesh, and the molecular basis of this resistance is a single 
point mutation in the AcrB protein, an efflux pump, at posi-
tion 717. This is the first report demonstrating the impact of 
this mutation in conferring azithromycin resistance in a clinical 
setting. All azithromycin-resistant strains were nonsusceptible 
to ciprofloxacin, ampicillin, co-trimoxazole, and chloram-
phenicol, and the only oral drug available for treatment was 
third-generation cephalosporin. As azithromycin is the only 
oral drug available to treat XDR S. Typhi, acquisition of the 
plasmid that confers cephalosporin-resistance in XDR strains 
by a Bangladeshi azithromycin-resistant strain or rise of a point 
mutation in the XDR strains can bring us to the brink of losing 
all antimicrobial weapons against typhoid. This poses serious 
threats to the health system of LMICs—an azithromycin-
resistant XDR strain would shift enteric fever treatment from 
the outpatient department, where patients are currently treated 
with oral azithromycin, to inpatient departments to be treated 
with injectable antibiotics such as carbapenems, weighing down 
already struggling health systems [35].
SALMONELLA ENTERICA SEROVAR PARATYPHI A: 
THE SIDEKICK
Typhoid and paratyphoid fever are often considered a single di-
sease, with the management of paratyphoid fever based on les-
sons learned from typhoid studies. However, there is growing 
realization in the scientific community that they are not iden-
tical diseases [36]. For example, S. Paratyphi A  (the primary 
cause of paratyphoid fever) has different AMR profiles than 
that of S. Typhi. A previous study from Bangladesh showed that 
MDR in Paratyphi A strains appears to be much less prevalent 
than in S. Typhi [37]. Furthermore, in comparison to children 
with typhoid, children with paratyphoid are more likely to be 
older, and are more often treated in the outpatient department 
[36]. As TCV does not protect against paratyphoid fever, and 
because S. Typhi and S. Paratyphi A exhibit different AMR pro-
files, disease dynamics and effectiveness of empirical therapy 
are likely to change in the near future. Therefore, gaining fur-
ther knowledge about S. Paratyphi A  is crucial, and in this 
conference, at least 23 presentations focused on AMR trends/
patterns of S. Paratyphi A in addition to S. Typhi, and 1 presen-
tation was dedicated to Paratyphi A only.
Corroborating with the published literature, the majority of 
studies noted that MDR (also defined as resistance to ampi-
cillin, chloramphenicol, and co-trimoxazole) is uncommon in 
S. Paratyphi A  strains. Presentations from Bangladesh, India, 
and Myanmar provided evidence of complete absence of MDR 
S. Paratyphi A in these 3 countries. However, Asif Khaliq from 
Aga Khan University Hospital in Pakistan reported the MDR 
rate of S. Paratyphi A  at 53%. Such high rates have not been 
reported elsewhere, including in the SEAP study, where the cur-
rent MDR rate of Paratyphi A is reported at 1% in Pakistan, and 
hence requires further investigation.
Saiful Islam Sajib presented data of about 2000 S. Paratyphi 
A strains from Bangladesh. This is the largest known historical 
dataset for Paratyphi A, and with data from the period 1999–
2016, he described absence of MDR but a rising trend in the 
minimum inhibitory concentration of ciprofloxacin among the 
Bangladeshi isolates. He demonstrated that low-cost restric-
tion fragment length polymorphism methods can be used to 
detect and monitor the circulating gyrase A mutations that lead 
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Typhi, almost all discussions concluded that decreased suscep-
tibility to fluoroquinolones is also commonly exhibited by S. 
Paratyphi A, and hence ciprofloxacin should not be a treatment 
of choice.
A study by Marie Chattaway from Public Health England re-
ported a travel-related ceftriaxone-resistant paratyphoid fever 
case, apparently originating in Bangladesh. This is the first re-
port of ceftriaxone-resistant Paratyphi A; however, none of the 
SEAP, STRATAA, or other long-term, extensive prospective 
studies conducted in Bangladesh, some for decades, reported 
any such observation. The molecular basis of this resistance was 
the carriage of a plasmid containing the blaCTX-M-15 extended-
spectrum β-lactamase gene, similar to the one detected by 
Djeghout et al in ceftriaxone-resistant S. Typhi [15]. If the find-
ings of this study are indeed correct, the phenomenon is of se-
rious concern and should be investigated further.
Similar to S. Typhi, azithromycin resistance is also emerging 
in S. Paratyphi A, and this was reported by authors from 
Bangladesh, India, and Nepal. However, these results should 
be cautiously examined. Dabet Rynga from India noted that 
assessing azithromycin resistance in S. Paratyphi A is difficult, 
as guidelines for azithromycin disk diffusion and minimum in-
hibitory concentration interpretive criteria by the Clinical and 
Laboratory Standards Institute exist only for S. Typhi, and not 
for S. Paratyphi A. The mechanism of azithromycin resistance 
in S. Paratyphi A  is conferred by the same single point mu-
tation in the AcrB efflux pump as that in S. Typhi (described 
above) [34].
THE PATH FORWARD
Salmonella Typhi is estimated to cause 10.92 million illnesses 
and 105 500 deaths, and S. Paratyphi A  to cause 3.39 million 
illnesses and 19  100 deaths every year [6]. Two-thirds of all 
etiologies of bloodstream infections from cases > 2 months of 
age in endemic countries comprise of S. Typhi or S. Paratyphi 
A  [38]. With increasing antibacterial resistance in typhoidal 
Salmonella and the dearth of novel antimicrobials on the ho-
rizon, we risk losing our primary defense against enteric fever, 
and returning to the preantibiotic era when the mortality rate 
was about 30%.
Introduction of the new TCV in endemic countries will be 
key in controlling typhoid. Data from the phase 3 clinical trial 
in Nepal are promising, and Pakistan has recently added TCV 
to its national immunization program. However, considering 
the overwhelming burden of typhoid, control of typhoid, and 
spread of AMR will require multipronged approaches. First, at 
present, typhoid vaccine is manufactured by only 1 company, 
and it may prove difficult for them to supply the millions of 
doses that will be required by all endemic countries. Therefore, 
deliberate strategies by companies, donors, and policymakers 
are very important for sustainable production and supply of 
TCV. Second, in addition to vaccines, to interrupt the trend 
of increasing AMR, local antibiotic stewardship led by public 
health officials and clinicians will be crucial. As AMR pat-
terns vary considerably between countries, empirical treatment 
guidelines should be designed based on local data. Third, we 
must also not lose sight of the fact that paratyphoid also poses 
a high burden, and rising AMR of S. Paratyphi A is also of se-
rious concern. Last but not least, we must remember that, his-
torically, WASH interventions have been the most successful in 
controlling enteric fever. Hence, it is imperative for local policy 
makers and international donors to continue their efforts and 
investments on WASH, which will help in the control of both 
typhoid and paratyphoid.
The fight against enteric fever calls for collective and compre-
hensive global and local action. Partnerships between local and 
international clinicians, public health officials, scientists, policy 
makers, and donors are imperative to win the arms race against 
rising AMR in enteric fever.
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